🟢 Abcellera Biologics is trading 8% up today in pre-market ahead of ABCL635 Phase 2 data

Abcellera Biologics is trading 8.06% up now at $7.49 after announcing it will release top-line Phase 2 data for ABCL635.

• The data will be released before the market opens on August 10, 2026.
• The trial evaluates a potential non-hormonal menopause treatment in approximately 80 postmenopausal women.
• An investor call is scheduled for 7:30 a.m. ET.